MA33840B1 - Nouveau composé de spiropipéridine - Google Patents
Nouveau composé de spiropipéridineInfo
- Publication number
- MA33840B1 MA33840B1 MA34993A MA34993A MA33840B1 MA 33840 B1 MA33840 B1 MA 33840B1 MA 34993 A MA34993 A MA 34993A MA 34993 A MA34993 A MA 34993A MA 33840 B1 MA33840 B1 MA 33840B1
- Authority
- MA
- Morocco
- Prior art keywords
- compound
- spiropiperidine compound
- novel spiropiperidine
- novel
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4747—Quinolines; Isoquinolines spiro-condensed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Diabetes (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
L'invention porte sur un composé de la formule, ou sur un sel pharmaceutiquement acceptable de celui-ci, ainsi que sur une composition pharmaceutique, et sur un procédé pour traiter le diabète.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US26518109P | 2009-11-30 | 2009-11-30 | |
PCT/US2010/057359 WO2011066183A1 (fr) | 2009-11-30 | 2010-11-19 | Nouveau composé de spiropipéridine |
Publications (1)
Publication Number | Publication Date |
---|---|
MA33840B1 true MA33840B1 (fr) | 2012-12-03 |
Family
ID=43384775
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA34993A MA33840B1 (fr) | 2009-11-30 | 2012-06-21 | Nouveau composé de spiropipéridine |
Country Status (25)
Country | Link |
---|---|
US (1) | US8822486B2 (fr) |
EP (1) | EP2507228B1 (fr) |
JP (1) | JP5709889B2 (fr) |
KR (1) | KR101410103B1 (fr) |
CN (1) | CN102648195B (fr) |
AR (1) | AR078948A1 (fr) |
AU (1) | AU2010324987B2 (fr) |
BR (1) | BR112012012903A2 (fr) |
CA (1) | CA2781292C (fr) |
CL (1) | CL2012001321A1 (fr) |
CR (1) | CR20120296A (fr) |
DO (1) | DOP2012000139A (fr) |
EA (1) | EA020507B1 (fr) |
EC (1) | ECSP12011930A (fr) |
ES (1) | ES2526568T3 (fr) |
GT (1) | GT201200164A (fr) |
IL (1) | IL219594A0 (fr) |
MA (1) | MA33840B1 (fr) |
MX (1) | MX2012006233A (fr) |
NZ (1) | NZ600203A (fr) |
PE (1) | PE20121474A1 (fr) |
TN (1) | TN2012000248A1 (fr) |
TW (1) | TW201141866A (fr) |
WO (1) | WO2011066183A1 (fr) |
ZA (1) | ZA201203055B (fr) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR078522A1 (es) | 2009-10-15 | 2011-11-16 | Lilly Co Eli | Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis |
PE20121639A1 (es) | 2009-12-25 | 2012-12-02 | Mochida Pharm Co Ltd | Derivados de 3-hidroxi-5-arilizotiazol como moduladores de gpr40 |
AU2011313191A1 (en) | 2010-10-08 | 2013-05-02 | Mochida Pharmaceutical Co., Ltd. | Cyclic amide derivative |
AU2012248629A1 (en) | 2011-04-27 | 2013-11-28 | Mochida Pharmaceutical Co., Ltd. | Novel 3-hydroxyisothiazole 1-oxide derivative |
JPWO2012147516A1 (ja) | 2011-04-28 | 2014-07-28 | 持田製薬株式会社 | 環状アミド誘導体 |
TWI537262B (zh) | 2011-08-17 | 2016-06-11 | 美國禮來大藥廠 | 供治療糖尿病使用之新穎1,2,3,4-四氫喹啉衍生物 |
ES2690145T3 (es) * | 2013-03-14 | 2018-11-19 | Janssen Pharmaceutica Nv | Agonistas de GPR120 para el tratamiento de diabetes de tipo 2 |
IN2013MU03577A (fr) | 2013-11-14 | 2015-07-31 | Cadila Healthcare Ltd | |
WO2015084692A1 (fr) | 2013-12-04 | 2015-06-11 | Merck Sharp & Dohme Corp. | Composés bicycliques antidiabétiques |
WO2015119899A1 (fr) | 2014-02-06 | 2015-08-13 | Merck Sharp & Dohme Corp. | Composés antidiabétiques |
WO2018166855A1 (fr) | 2017-03-16 | 2018-09-20 | Basf Se | Dihydroisoxazoles à substitution hétérobicyclique |
CR20200347A (es) | 2018-02-13 | 2020-09-23 | Gilead Sciences Inc | Inhibidores pd-1/pd-l1 |
CN112041311B (zh) | 2018-04-19 | 2023-10-03 | 吉利德科学公司 | Pd-1/pd-l1抑制剂 |
KR20230159715A (ko) | 2018-07-13 | 2023-11-21 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
AU2019366355B2 (en) | 2018-10-24 | 2022-10-13 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
CN110590767B (zh) * | 2019-08-29 | 2021-10-08 | 南方科技大学 | 一种合成amg837的方法 |
IL291985A (en) | 2019-10-07 | 2022-06-01 | Kallyope Inc | gpr119 agonists |
MX2022014505A (es) | 2020-05-19 | 2022-12-13 | Kallyope Inc | Activadores de la ampk. |
EP4172162A1 (fr) | 2020-06-26 | 2023-05-03 | Kallyope, Inc. | Activateurs d'ampk |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0202133D0 (sv) * | 2002-07-08 | 2002-07-08 | Astrazeneca Ab | Novel compounds |
WO2004089307A2 (fr) * | 2003-04-04 | 2004-10-21 | Merck & Co. Inc. | Derives de spiropiperidine acyles utilises comme agonistes vis-a-vis du recepteur de melanocortine-4 |
US7504506B2 (en) | 2003-11-04 | 2009-03-17 | Elixir Pharmaceuticals, Inc. | Therapeutic compounds and uses thereof |
CN1946666A (zh) * | 2004-02-27 | 2007-04-11 | 埃姆艮股份有限公司 | 用于治疗代谢性疾病的化合物、药物组合物和方法 |
JP4859665B2 (ja) * | 2004-03-30 | 2012-01-25 | 武田薬品工業株式会社 | アルコキシフェニルプロパン酸誘導体 |
DE602005014124D1 (de) * | 2004-09-07 | 2009-06-04 | Banyu Pharma Co Ltd | Carbamoylsubstituiertes spiro-derivat |
CN101553493B (zh) * | 2006-07-19 | 2012-07-04 | 阿斯利康(瑞典)有限公司 | 三环螺哌啶化合物、它们的合成和它们作为趋化因子受体活性调节剂的用途 |
CA2664358A1 (fr) * | 2006-09-28 | 2008-04-03 | Banyu Pharmaceutical Co., Ltd. | Derive de diarylcetimine |
CN101589046B (zh) * | 2006-12-29 | 2011-09-21 | 弗·哈夫曼-拉罗切有限公司 | 氮杂螺环衍生物 |
US7572934B2 (en) * | 2007-04-16 | 2009-08-11 | Amgen Inc. | Substituted biphenyl GPR40 modulators |
WO2009054479A1 (fr) * | 2007-10-26 | 2009-04-30 | Japan Tobacco Inc. | Compose spiro-cyclique et utilisation de ce compose a des fins medicales |
AR078522A1 (es) | 2009-10-15 | 2011-11-16 | Lilly Co Eli | Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis |
US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
-
2010
- 2010-11-08 AR ARP100104151A patent/AR078948A1/es not_active Application Discontinuation
- 2010-11-10 TW TW099138725A patent/TW201141866A/zh unknown
- 2010-11-19 JP JP2012542076A patent/JP5709889B2/ja not_active Expired - Fee Related
- 2010-11-19 AU AU2010324987A patent/AU2010324987B2/en not_active Ceased
- 2010-11-19 ES ES10784390.6T patent/ES2526568T3/es active Active
- 2010-11-19 WO PCT/US2010/057359 patent/WO2011066183A1/fr active Application Filing
- 2010-11-19 MX MX2012006233A patent/MX2012006233A/es not_active Application Discontinuation
- 2010-11-19 CA CA2781292A patent/CA2781292C/fr not_active Expired - Fee Related
- 2010-11-19 NZ NZ600203A patent/NZ600203A/xx not_active IP Right Cessation
- 2010-11-19 EP EP10784390.6A patent/EP2507228B1/fr active Active
- 2010-11-19 EA EA201290416A patent/EA020507B1/ru not_active IP Right Cessation
- 2010-11-19 PE PE2012000730A patent/PE20121474A1/es not_active Application Discontinuation
- 2010-11-19 CN CN201080054116.3A patent/CN102648195B/zh not_active Expired - Fee Related
- 2010-11-19 KR KR1020127013788A patent/KR101410103B1/ko not_active IP Right Cessation
- 2010-11-19 BR BR112012012903A patent/BR112012012903A2/pt not_active IP Right Cessation
- 2010-11-19 US US13/505,470 patent/US8822486B2/en not_active Expired - Fee Related
-
2012
- 2012-04-25 ZA ZA2012/03055A patent/ZA201203055B/en unknown
- 2012-05-03 IL IL219594A patent/IL219594A0/en unknown
- 2012-05-15 DO DO2012000139A patent/DOP2012000139A/es unknown
- 2012-05-20 EC ECSP12011930 patent/ECSP12011930A/es unknown
- 2012-05-22 TN TNP2012000248A patent/TN2012000248A1/en unknown
- 2012-05-23 CL CL2012001321A patent/CL2012001321A1/es unknown
- 2012-05-28 GT GT201200164A patent/GT201200164A/es unknown
- 2012-05-30 CR CR20120296A patent/CR20120296A/es not_active Application Discontinuation
- 2012-06-21 MA MA34993A patent/MA33840B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
ZA201203055B (en) | 2013-09-25 |
EA201290416A1 (ru) | 2012-11-30 |
BR112012012903A2 (pt) | 2017-03-01 |
NZ600203A (en) | 2013-09-27 |
KR101410103B1 (ko) | 2014-06-25 |
CN102648195A (zh) | 2012-08-22 |
CA2781292A1 (fr) | 2011-06-03 |
DOP2012000139A (es) | 2012-08-15 |
WO2011066183A1 (fr) | 2011-06-03 |
JP2013512277A (ja) | 2013-04-11 |
CA2781292C (fr) | 2014-04-22 |
AU2010324987A1 (en) | 2012-07-26 |
TN2012000248A1 (en) | 2013-12-12 |
CL2012001321A1 (es) | 2013-11-15 |
EP2507228A1 (fr) | 2012-10-10 |
ECSP12011930A (es) | 2012-07-31 |
CN102648195B (zh) | 2015-01-07 |
US20120220616A1 (en) | 2012-08-30 |
EA020507B1 (ru) | 2014-11-28 |
MX2012006233A (es) | 2012-07-03 |
TW201141866A (en) | 2011-12-01 |
EP2507228B1 (fr) | 2014-11-05 |
GT201200164A (es) | 2014-02-27 |
US8822486B2 (en) | 2014-09-02 |
AR078948A1 (es) | 2011-12-14 |
JP5709889B2 (ja) | 2015-04-30 |
KR20120088770A (ko) | 2012-08-08 |
AU2010324987B2 (en) | 2014-01-30 |
ES2526568T3 (es) | 2015-01-13 |
PE20121474A1 (es) | 2012-11-05 |
CR20120296A (es) | 2012-07-16 |
IL219594A0 (en) | 2012-06-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA33840B1 (fr) | Nouveau composé de spiropipéridine | |
MA33662B1 (fr) | Composés de spiropipéridine et leur utilisation pharmaceutique pour le traitement du diabète | |
MA35351B1 (fr) | Nouveau dérivé 1,2,3,4- tétrahydroquinoléine utile pour le traitement du diabète. | |
MA35128B1 (fr) | Nouveaux dérivés d'imidazole utiles pour le traitement de l'arthrite | |
IN2014MN02106A (fr) | ||
MA33636B1 (fr) | Dérivés aminopropioniques substitués comme inhibiteurs de néprilysine | |
MA35452B1 (fr) | 3-pyrimidin-4-yl-oxazolidin-2-ones comme inhibiteurs d'idh mutante | |
MA35432B1 (fr) | Composé pour le traitement et la prophylaxie de la maladie du virus respiratoire syncytial | |
MA34207B1 (fr) | Inhibiteurs de la pi3 kinase et/ou du mtor | |
MA35275B1 (fr) | Composés de tétrahydropyridopyridine et tétrahydropyridopyrimidine et utilisation de ceux-ci en tant que modulateurs de récepteur c5a | |
MA37888B1 (fr) | Composition pharmaceutique enrobée contenant du régorafenib | |
MX2013005826A (es) | Benzoxazepinas como inhibidores de fosfatidilinositol 3-cinasa/objetivo de rapamicina en mamiferos (p13k/mtor) y metodos de uso y fabricacion. | |
MA40895A (fr) | Synthèse de copanlisib et son sel de dichlorhydrate | |
MA32904B1 (fr) | Composes de purine | |
IN2014MN01521A (fr) | ||
MX2012003007A (es) | Sulfonamidas como inhibidores de las proteinas de la familia bcl-2 para el tratamiento de cancer. | |
WO2010110545A2 (fr) | Nouveau dérivé hydroxamate, procédé de production associé, et composition pharmaceutique comprenant le dérivé | |
MA39048A1 (fr) | Nouveaux inhibiteurs de la dgat2 | |
EP2416795A4 (fr) | Inhibiteurs de déclin cognitif | |
UA103329C2 (ru) | Соли соединений-ингибиторов вич | |
MA39983A (fr) | Dérivés de carboxamide | |
MA38410A1 (fr) | Composés d'azétidinyloxyphénylpyrrolidine | |
MX2016004265A (es) | Combinacion. | |
JO2999B1 (ar) | مركب ثلاثي حلقي و استخدامه الدوائي | |
MA38307A1 (fr) | 4-hydroxy-2-méthyl-5-(propan-2-ylidène)cyclohex-3-ènecarbaldéhyde pour la prévention et le traitement d'une maladie cognitive, neurodégénérative ou neuronale |